Merck Announces $6.7 Billion Acquisition of Terns Pharmaceuticals Following Drug Data
Merck announced last month its acquisition of Terns Pharmaceuticals for $6.7 billion. The deal follows promising early data from Terns' experimental leukemia drug. New details have emerged on the pricing negotiations.
Substrate placeholder — needs reviewMerck & Co. announced last month an agreement to acquire Terns Pharmaceuticals Inc. 7 billion in cash. The acquisition targets Terns' portfolio, including an experimental drug for leukemia. The deal includes $28 per share for Terns' outstanding shares, representing a 102% premium over the stock's closing price on the day before the announcement.
Terns' lead candidate, TERN-701, is an oral treatment for acute myeloid leukemia in development. Phase 1 trial data released earlier this year showed positive results, including high response rates among patients. The drug targets the menin protein, a mechanism aimed at addressing relapsed or refractory cases.
Deal The acquisition comes amid growing interest in oncology treatments.
Terns, based in Foster City, California, focuses on liver and oncology therapies. Merck, headquartered in Rahway, New Jersey, seeks to bolster its pipeline through this purchase. Negotiations for the deal reportedly began after the positive data readout for TERN-701.
According to STAT News, Merck valued the asset based on projected market potential and competitive risks in the leukemia space. 7 billion price reflects upfront payment plus potential milestones.
Terns will receive the cash consideration upon closing, expected in the first half of 2025, pending regulatory approvals.
S. Federal Trade Commission. Employees and ongoing trials at Terns are anticipated to integrate into Merck's operations. This acquisition affects investors in both companies, with Terns' stock surging on the announcement.
Broader implications include accelerated development of TERN-701 under Merck's resources. The leukemia treatment space involves patients with limited options, and the drug's progress could influence future therapies.
Key Facts
Story Timeline
3 events- Last month
Merck announced $6.7 billion acquisition of Terns Pharmaceuticals.
1 source@statnews - Earlier this year
Terns released promising Phase 1 data for leukemia drug TERN-701.
1 source@statnews - Post-data readout
Merck initiated negotiations leading to the acquisition price.
1 source@statnews
Potential Impact
- 01
Terns' shareholders receive $28 per share in cash upon deal closure.
- 02
Merck gains rights to TERN-701, potentially accelerating its development.
- 03
Regulatory scrutiny from FTC may delay the acquisition timeline.
- 04
Deal bolsters Merck's oncology portfolio amid competitive market.
- 05
Integration of Terns' staff supports continuity in ongoing trials.
Transparency Panel
Related Stories
news.sky.comWHO/ILO: 18,960 Non-Melanoma Skin Cancer Deaths in 2019 Attributed to Occupational Sun Exposure
Joint WHO and ILO estimates show 1.6 billion working-age people, or 28 percent of the global total, were exposed to solar ultraviolet radiation at work in 2019. The research links this exposure to 18960 non-melanoma skin cancer deaths that year across 183 countries. The organizat…
The Japan TimesIraq's Marshes See Partial Recovery as Water Levels Rise After Severe Drought
Rising water levels have begun restoring Iraq's southern marshes, with submerged areas increasing sharply and residents returning to previously abandoned zones. Heavy winter rains and deliberate releases from reservoirs have driven the recovery in the UNESCO World Heritage site o…
StatTrump Administration Announces Projected Savings From Drug Pricing Agreements
The Trump administration is touting massive projected savings from still-secret drug pricing deals even as outside experts question how independently verifiable the figures are. STAT reported on the claims alongside fresh accusations of political interference at the FDA, which wi…